> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Marks 50th Anniversary of Device Amendments
- URL: https://www.fdaweb.com/fda-marks-50th-anniversary-of-device-amendments/
- Published: 2026-05-28T12:00:00.000Z
- Updated: 2026-09-14T13:40:07.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5161218

FDA this week marked the 50th anniversary of the 1976 Medical Device Amendments by highlighting the law’s lasting role in shaping the modern oversight of medical devices. In a new *FDA Voices* [commentary](https://www.fda.gov/news-events/fda-voices/fifty-years-medical-device-amendments-building-strong-foundation-advance-safe-effective-and-high?utm%5Fmedium=email&utm%5Fsource=govdelivery), CDRH director **Michelle Tarver** said the amendments created the regulatory framework that continues to govern how medical devices are evaluated for safety and effectiveness in the U.S. FDA commemorated the anniversary this week with an event at its White Oak, MD, campus that brought together former agency leaders, alumni and current staff involved in device regulation.

Tarver described the Medical Device Amendments as a “landmark moment” that established a tailored regulatory approach for medical devices as technologies became more complex and increasingly central to healthcare delivery. “The goal remains at the heart of the FDA’s device regulation today,” Tarver wrote, referring to Congress’ objective of providing “reasonable assurance” that medical devices are safe and effective.

The 1976 law created the FDA’s three-tier device classification system, dividing products into Class 1, 2 and 3 categories based on risk. The framework also established the agency’s core premarket review pathways, including the premarket approval, or PMA, process and the 510(k) clearance pathway, both of which remain central to device regulation today.

Tarver said the structure has enabled FDA to regulate a broad range of products, from simple medical tools to complex life-sustaining technologies, while adapting to advances in science and engineering over the past five decades.

The commentary traced the origins of the legislation to growing concerns during the 1960s about medical device safety, including problems linked to the Dalkon Shield intrauterine device. It also referenced recommendations from the Cooper Committee Report, which proposed a risk-based classification framework that later became the basis for the amendments.

According to Tarver, the law also established foundational postmarket surveillance authorities, allowing the FDA to monitor devices after they enter commercial use and take corrective action when necessary.

Subsequent legislation, including the Safe Medical Devices Act and the Food and Drug Administration Modernization Act, expanded the agency’s authority and modernized its regulatory tools, she said. Tarver also pointed to emerging technologies such as artificial intelligence, digital health products, diagnostics and personalized medicine as areas that will continue to shape the agency’s future oversight efforts.

Tarver said the agency remains focused on maintaining a regulatory system that is “agile, science-based, and patient-centered” as medical technology continues to evolve.